Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment

Figures & data

Figure 1 Questions from the Osteoporosis Patient Satisfaction Questionnaire™ (OPSAT-Q™) used to assess gastrointestinal symptoms in the PRIOR and CURRENT studies.

Notes: *Question numbers refer to the numbers in the complete OPSAT-Q™. © for the OPSAT-Q Roche Laboratories, Inc. All Rights Reserved.

Table 1 Baseline and demographic characteristics

Characteristic	PRIOR: All participants (N = 543)	CURRENT: participants who reported GI symptoms during screening (n = 89)
Race
White/Caucasian	508 (94)	82 (92)
Black	15 (3)	4 (4)
Other	20 (4)	3 (3)
Age, years
n	543
Mean ± SD	66.0 ± 10.55	63.6 ± 10.62
Range	37–99	41–86
Weight, kg
n	540
Mean ± SD	65.0 ± 12.32
Range	37–125
Height, cm
n	541
Mean ± SD	159.8 ± 6.88
Range	130–182
BMI, kg/m^2
n	539
Mean ± SD	25.5 ± 4.88	25.8 ± 5.36
Range	14–49	17.8–42.1
Highest level of education
Elementary school	11 (2)
Some high school	35 (6)
High school graduate/GED	141 (26)
Some college	170 (31)
College graduate	130 (24)
Postgraduate degree	56 (10)
Current occupation
Not working	370 (68)
Working	173 (32)
Major risk factors for osteoporosis
Low body weight (<58 kg)	184 (33.9)	26 (29.2)
History of fractures as an adult	174 (32.0)	32 (36.0)
History of fragility fracture in 1st degree relative	126 (23.2)	15 (16.9)
Current smoker	60 (11.0)	11 (12.4)
Use of oral corticosteroid therapy for >3 months	53 (9.8)	5 (5.6)
None of above	168 (30.9)	24 (27.0)
Primary diagnosis
Osteoporosis	370 (68.1)	63 (70.8)
Osteopenia	173 (31.9)	26 (29.2)
Months since diagnosis, mean ± SD
Osteoporosis	–	57.1 ± 50.24 (n = 63)
Osteopenia	–	36.4 ± 23.63 (n = 26)
Months since stopping alendronate or risedronate
Mean ± SD	23.4 ± 25.82	–
Range	1.4–144.0	–
GI tolerance score
0 to <25	65 (12.0)
25 to <50	168 (31.1)
50 to <75	207 (38.3)
75 to ≤100	100 (18.5)
Total reported	540
Taking osteoporosis/osteopenia medication	0	89 (100)
Years of taking osteoporosis/osteopenia medication, mean ± SD (n = 87)	–	2.4 ± 1.9

Note: Data presented are number (%) unless otherwise noted.

Abbreviations: GED, general education development; GI, gastrointestinal; SD, standard deviation.

Figure 2 PRIOR: Change in self-reported gastrointestinal symptoms for patients with gastrointestinal symptoms at baseline (score of 1–4 on at least 1 of Osteoporosis Patient Satisfaction Questionnaire™ questions 11, 12, 13, 14, 15, 16) at Month 10.

Figure 3 CURRENT: Change in self-reported gastrointestinal symptoms for patients with gastrointestinal symptoms at baseline (score of 1–4 on at least 1 of Osteoporosis Patient Satisfaction Questionnaire™ questions 11, 12, 14, 15) at Month 6.